PMID- 23727436
OWN - NLM
STAT- MEDLINE
DCOM- 20140806
LR  - 20131209
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 76 Pt C
DP  - 2014 Jan
TI  - BDNF in fragile X syndrome.
PG  - 729-36
LID - S0028-3908(13)00231-1 [pii]
LID - 10.1016/j.neuropharm.2013.05.018 [doi]
AB  - Fragile X syndrome (FXS) is a monogenic disorder that is caused by the absence of 
      FMR1 protein (FMRP). FXS serves as an excellent model disorder for studies 
      investigating disturbed molecular mechanisms and synapse function underlying 
      cognitive impairment, autism, and behavioral disturbance. Abnormalities in 
      dendritic spines and synaptic transmission in the brain of FXS individuals and 
      mouse models for FXS indicate perturbations in the development, maintenance, and 
      plasticity of neuronal network connectivity. However, numerous alterations are 
      found during the early development in FXS, including abnormal differentiation of 
      neural progenitors and impaired migration of newly born neurons. Several aspects 
      of FMRP function are modulated by brain-derived neurotrophic factor (BDNF) 
      signaling. Here, we review the evidence of the role for BDNF in the developing 
      and adult FXS brain. This article is part of the Special Issue entitled 'BDNF 
      Regulation of Synaptic Structure, Function, and Plasticity'.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Castren, Maija L
AU  - Castren ML
AD  - Institute of Biomedicine/Physiology, University of Helsinki, P.O. Box 63, 
      FIN-00014 Helsinki, Finland; Rinnekoti Foundation, Rinnekodintie 10, FIN-02980 
      Espoo, Finland. Electronic address: Maija.Castren@helsinki.fi.
FAU - Castren, Eero
AU  - Castren E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130529
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (FMR1 protein, human)
RN  - 139135-51-6 (Fragile X Mental Retardation Protein)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*physiology/*therapeutic use
MH  - Fragile X Mental Retardation Protein/genetics
MH  - Fragile X Syndrome/*drug therapy/genetics/*metabolism
MH  - Gene Expression Regulation, Developmental/drug effects/genetics
MH  - Humans
MH  - Mice
MH  - Receptor, trkB/metabolism
MH  - Signal Transduction/drug effects/physiology
OTO - NOTNLM
OT  - 2-methyl-6-(phenylethynyl)pyridine hydrochloride
OT  - ADHD
OT  - Autism
OT  - BDNF
OT  - Brain-derived neurotrophic factor
OT  - CYFIP1
OT  - Circuit function
OT  - Differentiation
OT  - FMR1 gene
OT  - FMR1 protein
OT  - FMRP
OT  - FMRP-interacting protein
OT  - FXS
OT  - FXTAS
OT  - Fmr1 KO
OT  - Fmr1 gene
OT  - Fragile X syndrome
OT  - GABA
OT  - IP
OT  - LTD
OT  - LTP
OT  - MPEP
OT  - Mental retardation
OT  - N-methyl-d-aspartate receptor
OT  - NMDA
OT  - NPC
OT  - Neural progenitors
OT  - RNA interference
OT  - RNAi
OT  - TrkB receptor
OT  - aNPCs
OT  - adult neural progenitor cells
OT  - attention deficit and/or hyperactive disorder
OT  - fragile X mental retardation 1 gene
OT  - fragile X mental retardation 1 knockout
OT  - gamma-aminobutyric acid
OT  - gp1
OT  - group 1
OT  - intermediate progenitor
OT  - long-term depression
OT  - long-term potentiation
OT  - mGluR
OT  - metabotropic glutamate receptor
OT  - neural progenitor cells
OT  - tremor/ataxia syndrome
OT  - tropomyosin-related kinase B receptor
EDAT- 2013/06/04 06:00
MHDA- 2014/08/07 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/25 00:00 [received]
PHST- 2013/05/07 00:00 [revised]
PHST- 2013/05/08 00:00 [accepted]
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/08/07 06:00 [medline]
AID - S0028-3908(13)00231-1 [pii]
AID - 10.1016/j.neuropharm.2013.05.018 [doi]
PST - ppublish
SO  - Neuropharmacology. 2014 Jan;76 Pt C:729-36. doi: 
      10.1016/j.neuropharm.2013.05.018. Epub 2013 May 29.